Cargando…

Interstitial lung disease in systemic sclerosis: where do we stand?

Interstitial lung disease (ILD) is common in systemic sclerosis (SSc) patients and despite recent advances in the treatment is, at present, the major cause of death. Today, an early diagnosis of ILD is possible, and is mandatory to improve the prognosis of the disease. Pulmonary function tests and h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cappelli, Susanna, Bellando Randone, Silvia, Camiciottoli, Gianna, De Paulis, Amato, Guiducci, Serena, Matucci-Cerinic, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2015
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487695/ https://www.ncbi.nlm.nih.gov/pubmed/26324802 http://dx.doi.org/10.1183/16000617.00002915

Ejemplares similares

The “myth” of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event?
por: Matucci-Cerinic, Marco, et al.
Publicado: (2017)

Potential Role of JAK Inhibitors in the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease: A Narrative Review from Pathogenesis to Real-Life Data
por: Fiorentini, Elisa, et al.
Publicado: (2022)

The Role of Bronchoalveolar Lavage in Systemic Sclerosis Interstitial Lung Disease: A Systematic Literature Review
por: Orlandi, Martina, et al.
Publicado: (2022)

Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?
por: Bruni, Cosimo, et al.
Publicado: (2018)

The Role of Endogenous Eicosapentaenoic Acid and Docosahexaenoic Acid-Derived Resolvins in Systemic Sclerosis
por: Avanoǧlu Güler, Aslıhan, et al.
Publicado: (2020)

Lung Ultrasound B-Lines in the Evaluation of the Extent of Interstitial Lung Disease in Systemic Sclerosis
por: Bruni, Cosimo, et al.
Publicado: (2022)

Systemic Sclerosis Association with Malignancy
por: Lepri, Gemma, et al.
Publicado: (2022)

Systemic Sclerosis Patients Experiencing Mindfulness-Based Stress Reduction Program: The Beneficial Effect on Their Psychological Status and Quality of Life
por: El Aoufy, Khadija, et al.
Publicado: (2023)

Systemic Sclerosis Sera Impair Angiogenic Performance of Dermal Microvascular Endothelial Cells: Therapeutic Implications of Cyclophosphamide
por: Borghini, Annalisa, et al.
Publicado: (2015)

Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?
por: Harari, Sergio, et al.
Publicado: (2015)

Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do?
por: Bargagli, Elena, et al.
Publicado: (2019)

The crowded crossroad to angiogenesis in systemic sclerosis: where is the key to the problem?
por: Manetti, Mirko, et al.
Publicado: (2016)

The Emerging Challenge of Pain in Systemic Sclerosis: Similarity to the Pain Experience Reported by Sjőgren’s Syndrome Patients
por: De Luca, Rossella, et al.
Publicado: (2021)

The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress
por: Orlandi, Martina, et al.
Publicado: (2020)

Angiogenic T cell expansion correlates with severity of peripheral vascular damage in systemic sclerosis
por: Manetti, Mirko, et al.
Publicado: (2017)

Systemic Sclerosis Serum Significantly Impairs the Multi-Step Lymphangiogenic Process: In Vitro Evidence
por: Manetti, Mirko, et al.
Publicado: (2019)

Plexin-D1/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis
por: Mazzotta, Celestina, et al.
Publicado: (2015)

Proangiogenic effects of soluble α-Klotho on systemic sclerosis dermal microvascular endothelial cells
por: Mazzotta, Celestina, et al.
Publicado: (2017)

The Use and Utility of Machine Learning in Achieving Precision Medicine in Systemic Sclerosis: A Narrative Review
por: Bonomi, Francesco, et al.
Publicado: (2022)

Decreased expression of the endothelial cell-derived factor EGFL7 in systemic sclerosis: potential contribution to impaired angiogenesis and vasculogenesis
por: Manetti, Mirko, et al.
Publicado: (2013)

Lymphatic Endothelial-to-Myofibroblast Transition: A Potential New Mechanism Underlying Skin Fibrosis in Systemic Sclerosis
por: Rosa, Irene, et al.
Publicado: (2023)

Where Do We Stand?
Publicado: (1891)

Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases
por: Bruni, Cosimo, et al.
Publicado: (2022)

Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases
por: Bruni, Cosimo, et al.
Publicado: (2022)

Oral Lactobacillus Species in Systemic Sclerosis
por: Melchiorre, Daniela, et al.
Publicado: (2021)

Menstruation-Related Disorders—Dysmenorrhea and Heavy Bleeding—as Significant Epiphenomena in Women With Rheumatic Diseases
por: Orlandi, Martina, et al.
Publicado: (2022)

Ion Channels and Transporters in Immunity—Where do We Stand?
por: Hoeger, Birgit, et al.
Publicado: (2022)

Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases
por: Cometi, Laura, et al.
Publicado: (2020)

Gravity: where do we stand ?
por: Peron, Roberto, et al.
Publicado: (2016)

Addictive behaviors: where do we stand, and where are we going?
por: Thibaut, Florence, et al.
Publicado: (2017)

Exploring the Oral Microbiome in Rheumatic Diseases, State of Art and Future Prospective in Personalized Medicine with an AI Approach
por: Bellando-Randone, Silvia, et al.
Publicado: (2021)

Modeling Myxofibrosarcoma: Where Do We Stand and What Is Missing?
por: Lucarelli, Enrico, et al.
Publicado: (2023)

ColVI myopathies: where do we stand, where do we go?
por: Allamand, Valérie, et al.
Publicado: (2011)

Biomarkers for Alzheimer’s Disease: Where Do We Stand and Where Are We Going?
por: Villa, Chiara
Publicado: (2020)

Pixel Detectors ... where do we stand?
por: Wermes, Norbert
Publicado: (2019)

Laser accelerators : where do we stand
por: Lawson, J D
Publicado: (1985)

Renormalization schemes: where do we stand?
por: Ward, B F L
Publicado: (1990)

Barrett's Esophagus: Where Do We Stand?
por: Al Madi, Majid A.
Publicado: (2009)

Maximizing neuroprotection: where do we stand?
por: Kuffler, Damien P
Publicado: (2012)

LHC Access - Where do we Stand
por: Ninin, P, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_ilf8fhhg0nb1th1mckk65f8k3d